Cargando…

Injectables’ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes

BACKGROUND: Since a meta-analysis showed little or no effect of second-line injectables on treatment success, and using injectables may induce ototoxicity, injectable-free rifampicin-resistant tuberculosis (RR-TB) treatment regimens are recommended. However, acquired resistance preventing activity w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Decroo, Tom, Maug, Aung Kya Jai, Hossain, Mohamed Anwar, Uwizeye, Cécile, Gumusboga, Mourad, Demeulenaere, Tine, Ortuño-Gutiérrez, Nimer, de Jong, Bouke C., Van Deun, Armand
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458281/ https://www.ncbi.nlm.nih.gov/pubmed/32866193 http://dx.doi.org/10.1371/journal.pone.0238016

Ejemplares similares

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022)

The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance
por: Van Deun, Armand, et al.
Publicado: (2020)

Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen
por: Lempens, Pauline, et al.
Publicado: (2020)

Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings
por: Van Deun, Armand, et al.
Publicado: (2022)

High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
por: Decroo, Tom, et al.
Publicado: (2020)

Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi
por: Ciza, François, et al.
Publicado: (2020)

Should treatment of low-level rifampicin mono-resistant tuberculosis be different?
por: Van Deun, Armand, et al.
Publicado: (2021)

Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study
por: Souleymane, Mahamadou Bassirou, et al.
Publicado: (2022)

Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation
por: Souleymane, Mahamadou Bassirou, et al.
Publicado: (2022)

Borderline rpoB mutations transmit at the same rate as common rpoB mutations in a tuberculosis cohort in Bangladesh
por: Lempens, Pauline, et al.
Publicado: (2023)

Low Cycle Threshold Value in Xpert MTB/RIF Assay May Herald False Detection of Tuberculosis and Rifampicin Resistance: A Study of Two Cases
por: Ngabonziza, Jean Claude S, et al.
Publicado: (2021)

Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study
por: Hassane-Harouna, Souleymane, et al.
Publicado: (2020)

Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance
por: Torrea, Gabriela, et al.
Publicado: (2019)

Moxifloxacin concentration correlate with QTc interval in rifampicin-resistant tuberculosis patients on shorter treatment regimens
por: Kusmiati, Tutik, et al.
Publicado: (2022)

Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence
por: Trébucq, Arnaud, et al.
Publicado: (2019)

Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial
por: Phillips, P. P. J., et al.
Publicado: (2020)

High success and low recurrence with shorter treatment regimen for multidrug-resistant TB in Nepal
por: Koirala, S., et al.
Publicado: (2021)

Community-supported self-administered tuberculosis treatment combined with active tuberculosis screening: a pilot experience in Conakry, Guinea
por: Hassane-Harouna, Souleymane, et al.
Publicado: (2023)

Shorter TB treatment regimens should be safer as well
por: Rucsineanu, O., et al.
Publicado: (2023)

Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries
por: Schwœbel, Valérie, et al.
Publicado: (2020)

Drug-resistant tuberculosis: Progress towards shorter and safer regimens
por: Saravu, Kavitha, et al.
Publicado: (2019)

A shorter post-exposure prophylaxis regimen for rabies, Pakistan
por: Salahuddin, Naseem, et al.
Publicado: (2021)

Effectiveness and safety of bedaquiline-based, modified all-oral 9–11-month treatment regimen for rifampicin-resistant tuberculosis in Vietnam
por: Nguyen, Thi Mai Phuong, et al.
Publicado: (2023)

Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda
por: Habimana, Dominique Savio, et al.
Publicado: (2021)

Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review
por: Mallick, Jahan Saeed, et al.
Publicado: (2022)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis
por: Weyer, Karin, et al.
Publicado: (2018)

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial
por: Goodall, Ruth L, et al.
Publicado: (2022)

Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis
por: Tack, Ilse, et al.
Publicado: (2020)

Protocol, rationale and design of BE-PEOPLE (Bedaquiline enhanced exposure prophylaxis for LEprosy in the Comoros): a cluster randomized trial on effectiveness of rifampicin and bedaquiline as post-exposure prophylaxis of leprosy contacts
por: Younoussa, Assoumani, et al.
Publicado: (2023)

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis
por: Sweeney, Sedona, et al.
Publicado: (2022)

Shorter & cheaper regimen to treat multidrug-resistant tuberculosis: A new hope
por: Prasad, Rajendra, et al.
Publicado: (2017)

Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan
por: du Cros, Philipp, et al.
Publicado: (2021)

Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant Tuberculosis
por: Patankar, Sayalee, et al.
Publicado: (2023)

Shorter mothers have shorter pregnancies
por: Derraik, José, et al.
Publicado: (2015)

Population-Level Impact of Shorter-Course Regimens for Tuberculosis: A Model-Based Analysis
por: Fofana, Mariam O., et al.
Publicado: (2014)

The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets
por: Morgan, Jake R, et al.
Publicado: (2017)

Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone
por: Singh, Pravin K., et al.
Publicado: (2019)

Evaluation of Use of Shorter Radiation Regimens for Breast and Prostate Cancer in the US, 2015-2017
por: Gillespie, Erin F., et al.
Publicado: (2020)

Face mask sampling (FMS) for tuberculosis shows lower diagnostic sensitivity than sputum sampling in Guinea
por: Hassane-Harouna, Souleymane, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5lgr25ap90q9ls0a5mgaajk1u9